Fox Chase Cancer Center News

PHILADELPHIA (September 16, 2020)—This year, due to the COVID-19 pandemic, Fox Chase Cancer Center will hold its 21st annual Paws for the Cause dog walk virtually. The event, hosted by the Fox Chase Board of Associates, has raised more than $500,000 for cancer research at Fox Chase, and although this year’s format will be different, the goal is the same.

PHILADELPHIA (September 16, 2020)—Researchers at Fox Chase Cancer Center recently received a grant to study the molecular mechanisms regulating allogeneic T cell responses that could potentially prevent deaths following stem cell transplants.

PHILADELPHIA (September 15, 2020)—A researcher at Fox Chase Cancer Center recently published a paper addressing the practice of including social needs in gynecologic oncology.

PHILADELPHIA (September 14, 2020)—Researchers at Fox Chase Cancer Center and Temple University College of Public Health recently published survey results that explore the perceptions and concerns among African American patients regarding participation in cancer clinical trials.

PHILADELPHIA (September 14, 2020) — Fox Chase Cancer Center will present its signature fundraising event, In Vino Vita, on Friday, October 2, 2020, from 7–8 p.m. In order to maintain appropriate health and safety precautions, the 2020 gala was moved from its original spring date and will be held virtually for the first time in its seven-year history.

PHILADELPHIA (September 2, 2020)—Fox Chase Cancer Center’s Jeffrey Farma, MD, FACS, was recently admitted to the prestigious American College of Surgeons Academy of Master Surgeon Educators.

PHILADELPHIA (September 1, 2020) – September is National Prostate Cancer Awareness month. According to the American Cancer Society (ACS), prostate cancer is the most common cancer (aside from skin cancer) in American men. For 2020, the ACS is estimating approximately 191,130 new cases and nearly 33,330 deaths from prostate cancer.

PHILADELPHIA (August 31, 2020)—In a recent study, researchers at Fox Chase Cancer Center identified agents that can specifically target the histone-dependent route of PARP-1 activation. This novel approach appears to be able to target cancer cells better than traditional NAD-like PARP-1 inhibitors and could have potential for developing new treatments for urologic tumors.